![Jonathan Bernstein, MD, is a leading researcher in asthma and allergies.](https://www.uc.edu/news/articles/legacy/healthnews/2010/08/h11078/jcr:content/image.img.cq5dam.thumbnail.500.500.jpg/1534518022003.jpg)
UC Research Lends Hope for Patients With Rare Swelling Disease
CINCINNATIThe results of two recent clinical trials offer promising treatments for sufferers of the rare genetic disease hereditary angiodema, says Jonathan Bernstein, MD, an internationally recognized allergy specialist and researcher at the University of Cincinnati (UC).
"This is an orphan disease that until now hasnt been provided good treatments, says Bernstein, who co-authored two of three research articles on medicinal treatments for the disease that were published in the Aug. 5, 2010 issue of the New England Journal of Medicine.
Hereditary angioedema (HAE) is the spontaneous swelling of various body parts, including the hands, feet, face, stomach and airway, which is the most dangerous because it can lead to asphyxiation. According to the U.S. Hereditary Angioedema Association (HAEA), the disease occurs in about 1 in 10,000 to 1 in 50,000 people.
HAE is usually caused by a deficiency in the C1 esterase inhibitor enzyme.
"They either dont make enough of the C1 esterase inhibitor or it doesnt function properly, Bernstein explains, adding that research on the two treatments in which he participated provides evidence of prevention or symptom relief.
One of the trials Bernstein co-authored was sponsored by the pharmaceutical company Viropharma. This trial studied the intravenous injection of the C1 esterase inhibitor enzyme, harvested from the plasma of healthy donors. This replacement therapy showed beneficial effect in preventing swelling attacks, says Bernstein.
The second trial, which he says proved effective as well but is approved currently only in Europe, used a chemical receptor blocker to prevent the swelling, much like an antihistamine works to block histamine. This trial was sponsored by the pharmaceutical company Shire.
Historically, he says, the disease has been treated with anabolic steroids, the same steroidal treatment used by body builders to enhance muscle mass and performance, as these steroids have been shown to increase production of C1 esterase inhibitor in the liver. This treatment, he says, is effective for many patients but comes with potentially severe side effects such as liver toxicity, weight gain, lipid abnormalities, masculinization in women and increased risk for liver cancer.
"These findings provide a whole new avenue of treatment for a small patient population who suffer greatly, says Bernstein.
Current interest in the disease, he says, is the result of effective lobbying by the HAEA organization to gain the support of pharmaceutical companies in funding trials such as the ones conducted at the University of Cincinnati.
Bernstein is a paid consultant to Viropharma.
Tags
Related Stories
UC 1819 Innovation Hub partner takes health care from Cincinnati...
August 30, 2024
Christopher Lewis, founder of the Village Life Outreach Project and a professor of medicine at the University of Cincinnati, strives to boost health outcomes in his hometown and across the world in Tanzania.
How to fend off mosquitoes
![The New York Times logo](/content/dam/refresh/uc-news/news-icons/dark/nyt.png)
August 30, 2024
Mosquitoes can transmit pathogens that cause diseases, including West Nile virus and, in very rare cases, a disease known as Eastern equine encephalitis, or E.E.E. A UC expert spoke to the New York Times about simple precautions to keep mosquitoes away.
Study combines data, molecular simulations to accelerate drug...
August 30, 2024
Researchers from the University of Cincinnati College of Medicine and Cincinnati Children’s Hospital have found a new method to increase both speed and success rates in drug discovery. The study, published Aug. 30 in the journal Science Advances, offers renewed promise when it comes to discovering new drugs.